Mitoquinone (MitoQ) is a ubiquinone-derived antioxidant that can covalently attach to a lipophilic triphenylphosphonium (TPP) cation, specifically targets mitochondria.[1] MitoQ is usually stored within mitochondria in vivo in order to prevent and protect the cellular damage induced by mitochondrial ROS overproduction and oxidative stress.[2]
In vitro experiment it shown that washed platelets incubated with MitoQ 10 μM (4.8% ± 0.8%) markedly increased calcein-negative population (cytotoxic effect) compared to a non-treated control group; MitoQ 10 μM (8.5% ± 2.2%) induced a significant increase in PS exposure on the platelet membrane when compared to the basal control.[3] In addition, MitoQ (5 μM) inhibited collagen and ADP-induced platelet aggregation in PRP samples. In the meanwhile, MitoQ at 2.5 and 5 μM produced a obvious decrease in ROS production generated by antimycin A or collagen on platelet.[3]
In vivo, treatment with 2.5 mg/kg and 5 mg/kg MitoQ can alleviate mouse lung histologic changes induced by CS (Cigarette smoke).[1] In vivo experiment it shown that mitoquinone treatment with 10 mg/kg/day by gavage after 4 weeks, liver structure obiviously improved in association with a significant decrease in collagen deposition. In the meanwhile, mitoquinone treatment determined a significant reduction in hepatic inflammation and fibrosis. Moreover, TIMP-1, MMP-2, and MMP-13 gene expressions were decreased by Mitoquinone treatment.[4]
References:
[1]. Yang D, et al. Mitoquinone ameliorates cigarette smoke-induced airway inflammation and mucus hypersecretion in mice. Int Immunopharmacol. 2021 Jan;90:107149.
[2]. Chen W, et al. Inhibition of Mitochondrial ROS by MitoQ Alleviates White Matter Injury and Improves Outcomes after Intracerebral Haemorrhage in Mice. Oxid Med Cell Longev. 2020 Jan 4;2020:8285065.
[3]. Méndez D, et al. Mitoquinone (MitoQ) Inhibits Platelet Activation Steps by Reducing ROS Levels. Int J Mol Sci. 2020 Aug 27;21(17):6192.
[4]. Turkseven S, et al. Mitochondria-targeted antioxidant mitoquinone attenuates liver inflammation and fibrosis in cirrhotic rats. Am J Physiol Gastrointest Liver Physiol. 2020 Feb 1;318(2):G298-G304.
Mitoquinone (MitoQ) 是一种泛醌衍生的抗氧化剂，可以共价连接到亲脂性三苯基膦 (TPP) 阳离子上，专门针对线粒体。[1]MitoQ 通常储存在体内线粒体中，以便预防和保护由线粒体 ROS 过量产生和氧化应激引起的细胞损伤。[2]
体外实验表明，与未处理的对照组相比，用 MitoQ 10 μM (4.8% ± 0.8%) 孵育的洗涤过的血小板显着增加了钙黄绿素阴性群体（细胞毒性作用）；与基础对照相比，MitoQ 10 μM (8.5% ± 2.2%) 可显着增加血小板膜上的 PS 暴露。[3] 此外，MitoQ (5 μM) 可抑制胶原蛋白和 ADP -在 PRP 样品中诱导血小板聚集。同时，2.5 和 5 μM 的 MitoQ 显着降低抗霉素 A 或血小板上胶原蛋白产生的 ROS。[3]
在体内，用 2.5 mg/kg 和 5 mg/kg MitoQ 处理可以减轻 CS（香烟烟雾）引起的小鼠肺组织学变化。[1] 体内实验表明，mitoquinone 处理4 周后以 10 mg/kg/天的剂量灌胃，肝脏结构明显改善，胶原蛋白沉积显着减少。同时，线粒体醌治疗可显着减少肝脏炎症和纤维化。此外，丝裂醌处理降低了 TIMP-1、MMP-2 和 MMP-13 基因的表达。[4]